SK Life Science
NJ - Paramus
BiotechnologyFocus: Small Molecules for CNS
SK Life Science is a life sciences company focused on Small Molecules for CNS.
Neurology
Funding Stage
PUBLIC
Open Jobs
0
Products & Portfolio (1)
Pipeline & Clinical Trials
YKP3089
Partial EpilepsyClinical Trials (1)
NCT04513860Cenobamate Expanded Access Program (EAP)
N/AAlprazolam Placebo
Healthy VolunteerClinical Trials (1)
NCT03509285A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users
Phase 1Xcopri
Partial EpilepsyClinical Trials (1)
NCT04903314Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures
Phase 1Cenobamate 200Mg Tab Fasted
HealthyClinical Trials (1)
NCT04690751Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and Tablet
Phase 1Carisbamate
Lennox Gastaut SyndromeClinical Trials (1)
NCT04062981Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
Phase 1Cenobamate
Healthy VolunteersClinical Trials (1)
NCT05572255A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally
Phase 1Carisbamate
Lennox Gastaut SyndromeClinical Trials (1)
NCT03731715Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome
Phase 1Carisbamate
Healthy SubjectsClinical Trials (1)
NCT04520360Bioavailability and Food Effect Study of 3 Types of Carisbamate
Phase 1SKL24741
HealthyClinical Trials (1)
NCT04505397Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects
Phase 1Cenobamate
HealthyClinical Trials (1)
NCT03234699Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug Interactions
Phase 1Cenobamate
Hepatic ImpairmentClinical Trials (1)
NCT04791553Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment
Phase 1SKL15508
SchizophreniaClinical Trials (1)
NCT02205099A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia
Phase 1/2SKL27969
Advanced Solid TumorClinical Trials (1)
NCT05388435Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
Phase 1/2Carisbamate
Essential Tremor, Movement DisordersClinical Trials (1)
NCT00524056A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor
Phase 2SKL11197
Painful Diabetic NeuropathyClinical Trials (1)
NCT01521598A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy
Phase 2Pregabalin 300 mg/d
Diabetic NeuropathiesClinical Trials (1)
NCT00870454An Efficacy and Safety Study of Carisbamate in the Treatment of Nerve Pain in Diabetics
Phase 2YKP3089
Partial EpilepsyClinical Trials (1)
NCT01866111A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Phase 2Placebo Capsule
Chronic ConstipationClinical Trials (1)
NCT01523184A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation
Phase 2YKP3089
Partial EpilepsyClinical Trials (1)
NCT01397968Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures
Phase 2YKP10811
Chronic Idiopathic ConstipationClinical Trials (1)
NCT01989234A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation
Phase 2RWJ 333369
EpilepsyClinical Trials (1)
NCT00210522An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy
Phase 2RWJ-333369
Migraine HeadachesClinical Trials (1)
NCT00109083A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine
Phase 2RWJ-333369
Refractory EpilepsyClinical Trials (1)
NCT00228969Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy
Phase 2RWJ 333369:
EpilepsyClinical Trials (1)
NCT00210652An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With Epilepsy
Phase 2YKP3089
EpilepsyClinical Trials (1)
NCT00616148Efficacy of YKP3089 in Patients With Photosensitive Epilepsy
Phase 2placebo
Postherpetic NeuralgiaClinical Trials (1)
NCT00492323An Effectiveness and Safety Study With RWJ-333369 (Carisbamate) for the Study of Postherpetic Neuralgia (PHN).
Phase 2placebo
Diabetic Neuropathy, PainfulClinical Trials (1)
NCT00501202Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).
Phase 2RWJ-333369
EpilepsyClinical Trials (1)
NCT00433667A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.
Phase 3Xcopri
Partial EpilepsyClinical Trials (1)
NCT05067634Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
Phase 3Carisbamate
SeizuresClinical Trials (1)
NCT05219617Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Phase 3Cenobamate
Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized EpilepsyClinical Trials (1)
NCT03961568Cenobamate Open-Label Extension Study for YKP3089C025
Phase 3RWJ-333369
SeizuresClinical Trials (1)
NCT00697762Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures
Phase 3Cenobamate
Partial SeizureClinical Trials (1)
NCT04557085Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS
Phase 3RWJ-333369
EpilepsyClinical Trials (1)
NCT00425282A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.
Phase 3Cenobamate
Primary Generalized EpilepsyClinical Trials (1)
NCT03678753Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures
Phase 3Carisbamate
Epilepsy, Partial, MotorClinical Trials (1)
NCT00740623A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.
Phase 3placebo
Epilepsy, Partial, MotorClinical Trials (1)
NCT00744731An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures
Phase 3carisbamate
EpilepsyClinical Trials (1)
NCT00563459Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.
Phase 3YKP3089
Partial EpilepsyClinical Trials (1)
NCT02535091Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Phase 3RWJ-333369
SeizuresClinical Trials (1)
NCT00697918Long Term Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures
Phase 3carisbamate
EpilepsyClinical Trials (1)
NCT00991757An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.
Phase 3Cenobamate
Focal Onset SeizureClinical Trials (1)
NCT06453213Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
Phase 4Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 1953
Portfolio: 1 approved product, 42 clinical trials
Portfolio Health
Peak1 (100%)
1 total products
Hiring Trend
Stable
0
Open Roles
+0
Added
-0
Filled/Removed
Based on last 3 crawl cycles